Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Share-based Compensation (2019 - 2026)

Enliven Therapeutics has reported Share-based Compensation over the past 8 years, most recently at $7.4 million for Q1 2026.

  • Quarterly results put Share-based Compensation at $7.4 million for Q1 2026, up 8.8% from a year ago — trailing twelve months through Mar 2026 was $34.6 million (up 54.14% YoY), and the annual figure for FY2025 was $34.0 million, up 68.63%.
  • Share-based Compensation reached $7.4 million in Q1 2026 per ELVN's latest filing, down from $12.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $12.3 million in Q4 2025 and bottomed at $654000.0 in Q1 2022.
  • Median Share-based Compensation over the past 5 years was $4.5 million (2024), compared with a mean of $4.6 million.
  • The largest annual shift saw Share-based Compensation crashed 30.94% in 2022 before it soared 498.43% in 2023.
  • Over 5 years, Share-based Compensation stood at $735000.0 in 2022, then skyrocketed by 315.78% to $3.1 million in 2023, then surged by 74.71% to $5.3 million in 2024, then skyrocketed by 130.59% to $12.3 million in 2025, then tumbled by 39.92% to $7.4 million in 2026.
  • Business Quant data shows Share-based Compensation for ELVN at $7.4 million in Q1 2026, $12.3 million in Q4 2025, and $7.2 million in Q3 2025.